Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Apnimed, Inc.

APMDNASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Aug 3, 2026Accepted Aug 3, 2026, 4:01 PM EDTFiling CIK 1745648Accession 0001193125-26-330507
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-07-30
Issuer
Apnimed, Inc.
Issuer CIK
0001745648
Trading symbol
APMD

Reporting owner 1

Name
SEKHRI PAUL J
Reporting owner CIK
0001264519
Relationship
Director
Address
APNIMED, INC., 39 JOHN F. KENNEDY STREET, 4TH FLOOR, CAMBRIDGE, MA, 02138

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-08-03P · Form 412,500A16.0012,500D
Table key
P · Form 4
Purchase on the market or privately
A
Acquired
D
Direct

Derivative transactions

Derivative transactions · 8 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to Buy)8.152026-08-03D · Form 4[F1]169,468D0[F2]2036-05-28Class A Common Stock169,4680D
Stock Option (Right to Buy)8.152026-08-03A · Form 4[F1]169,468A0[F2]2036-05-28Common Stock169,468169,468D
Stock Option (Right to Buy)16.002026-07-30A · Form 4155,558A0[F2]2036-07-29Class A Common Stock155,558155,558D
Stock Option (Right to Buy)16.002026-08-03D · Form 4[F1]155,558A0[F2]2036-07-29Class A Common Stock155,5580D
Stock Option (Right to Buy)16.002026-08-03A · Form 4[F1]155,558A0[F2]2036-07-29Common Stock155,558155,558D
Stock Option (Right to Buy)16.002026-07-30A · Form 422,238A0[F3]2036-07-29Class A Common Stock22,23822,238D
Stock Option (Right to Buy)16.002026-08-03D · Form 4[F1]22,238D0[F3]2036-07-29Class A Common Stock22,2380D
Stock Option (Right to Buy)16.002026-08-03A · Form 4[F1]22,238A0[F3]2036-07-29Common Stock22,23822,238D
Table key
D · Form 4
Disposition to the issuer under Rule 16b-3(e)
D
Direct
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired

Footnotes

F1
Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6
F2
One-third of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 24 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.↩ 1↩ 2↩ 3↩ 4↩ 5
F3
The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.↩ 1↩ 2↩ 3

Signature 1

Signed
/s/Kevin R. Lind, Attorney-in-Fact
Date
2026-08-03

Company context

We are a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. Our sole clinical product candidate, AD109 (Oxnimbi), is an investigational, fixed-dose, anti-apneic neuromuscular modulator, combining a novel anti-muscarinic and a selective norepinephrine reuptake inhibitor (NRI) for the treatment of obstructive sleep apnea (OSA). Oxnimbi is designed to target the neuromuscular defect of OSA by improving upper airway muscle activity to help maintain airway patency and prevent airway collapse during sleep. Based on results from two registrational trials, we submitted a New Drug Application (NDA) for Oxnimbi to the U.S. Food and Drug Administration (FDA) in April 2026, which was accepted for review by the FDA in July 2026. The registrational trials were Phase 3, randomized, double-blind, placebo-controlled, parallel-arm trials in adults with mild to severe OSA, LunAIRo and SynAIRgy, which together enrolled approximately 1,300 patients and represent one of the largest and most diverse cohorts ever studied in an OSA pharmacologic trial. LunAIRo was conducted in the United States and SynAIRgy was conducted in the United States and Canada. All previous trials of Oxnimbi were conducted in the United States. In this prospectus, we also refer to AD109 by its proposed future brand name, “Oxnimbi.” This brand name was conditionally approved by the F

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by Miller Lawrence G. regarding Apnimed, Inc.Nov 16, 2026
  2. SCHEDULE 13G - filed by Morningside Venture Investments Ltd regarding Apnimed, Inc.Nov 16, 2026
  3. 10-Q filingNov 16, 2026
  4. Results of Operations and Financial ConditionNov 16, 2026
  5. 10-Q/A filingNov 13, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.